Volume 28, Number 1—January 2022
Synopsis
Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India
Table 1
Clinical characteristics of patients experiencing intensive rhino-sino-orbital and cerebral mucormycosis after undergoing treatment for COVID-19, India
Characteristic | No. case-patients, n = 178 |
---|---|
Age | |
Age, y, median (range) | 51 (42–60) |
Age group | |
<18 | 1 (1) |
18–45 | 52 (29) |
45–65 | 103 (58) |
>65 |
22 (12) |
Sex | |
M | 125 (70) |
F |
53 (30) |
Underlying illness | |
Diabetes mellitus | |
Previously diagnosed | 88 (49) |
Newly diagnosed | 44 (25) |
Hypertension | 48 (27) |
Chronic kidney disease | 5 (3) |
Cardiomyopathy | 4 (2) |
Asthma | 2 (1) |
HIV |
1 (1) |
COVID-19 characteristics† | |
Moderate COVID-19 | 122 (77) |
Mild COVID-19 | 29 (18) |
Severe COVID-19 | 8 (5) |
Hospitalization, d, median (IQR) | 10 (8–15) |
Required oxygenation | 103 (69) |
Required ventilator support | 5 (4) |
Received intravenous steroids | 82 (67) |
Received oral steroids | 12 (17) |
Received antimicrobial drugs |
95 (98) |
Symptoms of mucormycosis | |
Facial pain | 132 (74) |
Headache | 96 (54) |
Nasal congestion | 79 (44) |
Nasal discharge | 57 (32) |
Vision impairment | 66 (37) |
Time from COVID-19 diagnosis to mucormycosis symptom onset, d (IQR) |
28 (15–45) |
Vital signs | |
Temperature, °F, median (IQR) | 98 (98–98.6) |
Heart rate >100 beats/min | 4 (2) |
Heart rate, beats/min, median (IQR) | 88 (86–90) |
Respiratory rate >20 breaths/min | 29 (16) |
Respiratory rate, breaths/min, median (IQR) | 16 (12–18) |
Median BP, systolic, mm Hg | 123 (120–128) |
Median BP, diastolic, mm Hg | 80 (80–86) |
*Values are no. (%) patients except as indicated. BP, blood pressure; COVID-19, coronavirus disease; IQR, interquartile range. †These characteristics represent diagnosis and treatment provided for COVID-19 prior to mucormycosis events.